Alnylam Pharmaceuticals' (ALNY) Outperform Rating Reiterated at William Blair

William Blair reaffirmed their outperform rating on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY - Free Report) in a report issued on Friday,RTT News reports.

Other equities research analysts have also recently issued reports about the company. Morgan Stanley increased their price objective on Alnylam Pharmaceuticals from $275.00 to $284.00 and gave the company an "equal weight" rating in a research report on Friday, February 14th. StockNews.com lowered shares of Alnylam Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Friday. Royal Bank of Canada restated an "outperform" rating and set a $310.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Wednesday, February 26th. Sanford C. Bernstein dropped their target price on shares of Alnylam Pharmaceuticals from $314.00 to $310.00 and set an "outperform" rating on the stock in a report on Tuesday, January 7th. Finally, HC Wainwright boosted their target price on shares of Alnylam Pharmaceuticals from $400.00 to $500.00 and gave the company a "buy" rating in a research note on Monday, February 24th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and twenty have given a buy rating to the stock. Based on data from MarketBeat.com, Alnylam Pharmaceuticals presently has an average rating of "Moderate Buy" and a consensus price target of $312.30.

Remove Ads

Alnylam Pharmaceuticals Stock Down 3.4 %

ALNY traded down $9.74 during midday trading on Friday, reaching $280.96. The company's stock had a trading volume of 1,065,379 shares, compared to its average volume of 806,039. Alnylam Pharmaceuticals has a 1 year low of $141.98 and a 1 year high of $304.39. The firm has a market capitalization of $36.37 billion, a price-to-earnings ratio of -129.47 and a beta of 0.39. The stock's 50-day moving average is $258.62 and its 200-day moving average is $260.26. The company has a current ratio of 2.78, a quick ratio of 2.71 and a debt-to-equity ratio of 15.27.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last issued its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by ($0.03). As a group, research analysts expect that Alnylam Pharmaceuticals will post -1.7 EPS for the current year.

Insider Transactions at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 1,213 shares of the company's stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $255.17, for a total value of $309,521.21. Following the completion of the transaction, the chief executive officer now directly owns 81,526 shares in the company, valued at $20,802,989.42. This represents a 1.47 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Kevin Joseph Fitzgerald sold 663 shares of the stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $255.21, for a total transaction of $169,204.23. Following the sale, the executive vice president now directly owns 14,321 shares of the company's stock, valued at approximately $3,654,862.41. This trade represents a 4.42 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 71,234 shares of company stock valued at $19,958,097 over the last three months. Corporate insiders own 1.50% of the company's stock.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Capital World Investors increased its holdings in Alnylam Pharmaceuticals by 0.6% in the 4th quarter. Capital World Investors now owns 16,600,525 shares of the biopharmaceutical company's stock valued at $3,906,284,000 after acquiring an additional 92,101 shares during the last quarter. Vanguard Group Inc. increased its holdings in shares of Alnylam Pharmaceuticals by 0.8% in the fourth quarter. Vanguard Group Inc. now owns 12,733,399 shares of the biopharmaceutical company's stock worth $2,996,296,000 after purchasing an additional 98,303 shares during the last quarter. Capital Research Global Investors lifted its position in shares of Alnylam Pharmaceuticals by 32.9% in the fourth quarter. Capital Research Global Investors now owns 6,968,513 shares of the biopharmaceutical company's stock worth $1,639,767,000 after buying an additional 1,724,610 shares in the last quarter. Regeneron Pharmaceuticals Inc. purchased a new stake in shares of Alnylam Pharmaceuticals in the fourth quarter worth about $1,045,822,000. Finally, T. Rowe Price Investment Management Inc. grew its holdings in Alnylam Pharmaceuticals by 39.7% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 4,384,449 shares of the biopharmaceutical company's stock valued at $1,031,705,000 after buying an additional 1,245,195 shares in the last quarter. Institutional investors own 92.97% of the company's stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.